Novo’s continuing supply problems for semaglutide comes as the pharma tries to expand the drug’s indication, opening it up to more patients—and potentially to heavier production pressures.
Novo’s continuing supply problems for semaglutide comes as the pharma tries to expand the drug’s indication, opening it up to more patients—and potentially to heavier production pressures.